This approval is a transformative catalyst for SPRO, likely driving a significant re-rating as the company transitions to commercial stage with a partnered asset. Monitor launch execution, initial prescription trends, and any milestone payments from GSK. The stock may gap up sharply on open; consider positioning for sustained upside through the end-of-2026 launch window.
SPRO drugs
SPRO drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 17 $2.11entry
- T+1 · 5mo ago +8.06%α +7.28% · $2.28
- T+5 · 5mo ago −0.47%α +0.57% · $2.10
- T+20 · 4mo ago −25.59%α −26.91% · $1.57
- T+60 · 2mo ago −46.45%α −49.59% · $1.13
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Spero Therapeutics and GSK announced FDA approval of Utebzi (tebipenem pivoxil), the first oral carbapenem antibiotic for complicated urinary tract infections (cUTIs) in adults with limited or no alternative oral options. The approval, based on the PIVOT-PO Phase III trial demonstrating non-inferiority to IV imipenem-cilastatin, transforms Spero from a clinical-stage to a commercial-stage biopharma company and unlocks a $6B+ annual US healthcare cost market with GSK as commercialization partner.
Key Facts
- FDA approved Utebzi (tebipenem pivoxil) for cUTIs including pyelonephritis, first and only oral carbapenem antibiotic in the US
- Approval based on PIVOT-PO Phase III trial: 58.5% overall success rate (oral) vs 60.2% (IV imipenem-cilastatin); adjusted treatment difference −1.3% (95% CI −7.5%, 4.8%)
- GSK holds exclusive global license (excluding select Asian territories) and will lead commercialization; Spero sub-licensed back for certain development work
- Product anticipated to be available to US patients by end of 2026
- More than 3 million cUTI cases annually in the US, with $6+ billion in healthcare costs; up to 34% of patients experience treatment failure
Financial Impact
First oral carbapenem addressing a $6+ billion annual US healthcare cost market for cUTIs; transforms Spero from clinical-stage to commercial-stage with GSK as partner
Risk Factors
- Commercial execution risk, first launch for Spero, though GSK provides infrastructure
- Competition from existing IV carbapenems and other oral antibiotics for cUTI
- Post-market safety surveillance could reveal new adverse events
- Pricing and reimbursement uncertainty in the antibiotic space
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3313706 |
Track record
17 reports on SPRO
4 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +14.59% at T+20 after the Mar 26, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $0.9999 Now $0.9460 −5.39% settles Nov 20
- Nov 10, 20266d ago 3 Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
- Nov 10, 20266d ago 8-K Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
- Oct 27, 202620d ago 8-K Neutral 2/10 Entry $1.17 to $1.07 Now $0.9460 −19.15% ▼ −8.55% −7.83% vs SPY
- Sep 11, 20269w ago EFFECT Bearish 7/10 Entry $1.13 to $1.13 Now $0.9460 +16.28% · 0.00% −0.34% vs SPY
- Aug 28, 202611w ago 8-K Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
- Aug 28, 202611w ago S-3 Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
- Aug 12, 202613w ago Press Release Neutral 4/10 Entry $1.24 to $1.22 Now $0.9460 −23.71% ▼ −1.61% +0.35% vs SPY
- Jul 14, 202617w ago 8-K Bullish 8/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
- Jul 14, 202617w ago Press Release Bullish 7/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers